|
Re: FDA approves drug that reduces MACE in Diabetes patients (Forbes)
|
5
|
Resverlogix Corp.
|
Jun 14, 2016 07:21AM
|
|
Re: New publication: RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
|
2
|
Zenith Epigenetics
|
Jun 14, 2016 07:25AM
|
|
Re: FDA approves drug that reduces MACE in Diabetes patients (Forbes)
|
4
|
Resverlogix Corp.
|
Jun 14, 2016 11:01AM
|
|
Re: The new competitors: SGLT2 inhibitors and GLP-1 Receptor Agonists
|
3
|
Resverlogix Corp.
|
Jun 14, 2016 11:25AM
|
|
PROTAC-mediated BET degradation as a therapeutic strategy in CRPC
|
4
|
Zenith Epigenetics
|
Jun 14, 2016 12:00PM
|
|
Re: Inflection Points: Resverlogix and Zenith
|
3
|
Resverlogix Corp.
|
Jun 14, 2016 01:40PM
|
|
ESC 2016 Symposium
|
6
|
Resverlogix Corp.
|
Jun 15, 2016 12:52PM
|
|
Re: ESC 2016 Symposium
|
2
|
Resverlogix Corp.
|
Jun 15, 2016 01:53PM
|
|
Re: TRIALS SITE/ SHOWS TWO APPROVED TRIALS
|
3
|
Zenith Epigenetics
|
Jun 16, 2016 09:24AM
|
|
Re: TRIALS SITE/ SHOWS TWO APPROVED TRIALS
|
3
|
Zenith Epigenetics
|
Jun 16, 2016 10:53AM
|
|
Re: TRIALS SITE/ SHOWS TWO APPROVED TRIALS
|
2
|
Zenith Epigenetics
|
Jun 16, 2016 12:27PM
|
|
Re: TRIALS SITE/ SHOWS TWO APPROVED TRIALS
|
3
|
Zenith Epigenetics
|
Jun 16, 2016 01:22PM
|
|
Re: What Monday Brings?
|
6
|
Zenith Epigenetics
|
Jun 16, 2016 11:26PM
|
|
Re: What Monday Brings?
|
6
|
Zenith Epigenetics
|
Jun 17, 2016 09:36AM
|
|
New Zealand Renal Phase 1 Trial with RVX-208
|
4
|
Resverlogix Corp.
|
Jun 17, 2016 12:45PM
|
|
Re: I'm not ready to throw DM and other management under the bus...
|
7
|
Resverlogix Corp.
|
Jun 20, 2016 11:44AM
|
|
Re: I'm not ready to throw DM and other management under the bus...
|
4
|
Resverlogix Corp.
|
Jun 20, 2016 12:52PM
|
|
Re: Corporate Update Webcast... 11:00 MT/1:00 ET... Link-->
|
1
|
Zenith Epigenetics
|
Jun 20, 2016 12:56PM
|
|
Re: Corporate Update Webcast... 11:00 MT/1:00 ET... Link-->
|
3
|
Zenith Epigenetics
|
Jun 20, 2016 01:47PM
|
|
Re: ZENITH CALL
|
2
|
Zenith Epigenetics
|
Jun 20, 2016 01:52PM
|
